Patent · US Active

Pharmaceutical composition of an anti-VEGF antibody

US10568951B2 · kind B2 · utility

5Cited by
5References
11Claims
0Family size

Assignee

Inventor

Key dates

Filing dateNov 13, 2014
Grant dateFeb 25, 2020
Priority date
Expiry dateJul 23, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to liquid pharmaceutical formulations for intravitreal injection of an anti-VEGF antibody which does not contain saccharides for use in the treatment of age-related macular degeneration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.